MGNX
MacroGenics, Inc. NASDAQ Listed Oct 10, 2013$2.94
After hrs
$3.00
+0.00%
Mkt Cap $186.5M
52w Low $1.19
64.9% of range
52w High $3.88
50d MA $2.97
200d MA $1.98
P/E (TTM)
-2.6x
EV/EBITDA
-2.3x
P/B
3.6x
Debt/Equity
1.9x
ROE
-134.2%
P/FCF
-1.2x
RSI (14)
—
ATR (14)
—
Beta
1.10
50d MA
$2.97
200d MA
$1.98
Avg Volume
1.0M
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
9704 Medical Center Drive · Rockville, MD 20850 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -0.42 | -0.22 | +47.6% | 2.36 | +2.5% | +45.3% | +41.5% | +32.2% | +27.1% | +31.4% | — |
| Nov 12, 2025 | AMC | -0.48 | 0.27 | +156.2% | 1.47 | +12.9% | +8.8% | +2.0% | +2.7% | +4.8% | -3.4% | — |
| Aug 14, 2025 | AMC | -0.59 | -0.57 | +3.4% | 1.62 | -1.2% | -2.5% | -6.2% | -8.0% | -8.0% | -11.1% | — |
| May 13, 2025 | AMC | -0.61 | -0.65 | -6.6% | 1.54 | -1.3% | +0.6% | +0.0% | +2.6% | +3.2% | +1.9% | — |
| Mar 20, 2025 | AMC | -0.23 | -0.25 | -8.7% | 2.10 | -1.0% | -4.8% | -6.7% | -14.8% | -25.7% | -29.5% | — |
| Nov 5, 2024 | AMC | 0.21 | 0.90 | +328.6% | 3.77 | +21.8% | +11.1% | +18.3% | +15.4% | +16.4% | +8.8% | — |
| Aug 6, 2024 | AMC | -0.47 | -0.89 | -89.4% | 3.64 | -3.8% | -7.1% | -5.2% | -3.3% | -8.0% | -3.0% | — |
| May 9, 2024 | AMC | -0.67 | -0.84 | -25.4% | 14.67 | -69.1% | -77.4% | -70.1% | -69.7% | -67.9% | -65.1% | — |
| Mar 7, 2024 | AMC | -0.26 | -0.75 | -188.5% | 20.51 | -5.7% | -15.0% | -17.4% | -14.2% | -19.3% | -21.7% | — |
| Nov 6, 2023 | AMC | -0.11 | -0.52 | -392.9% | 5.44 | +7.9% | +17.1% | +26.7% | +20.4% | +17.6% | +17.1% | — |
| Aug 9, 2023 | AMC | -0.52 | -0.36 | +30.8% | 4.98 | +2.8% | +24.3% | +19.1% | +11.6% | +7.6% | +5.0% | — |
| May 9, 2023 | AMC | 1.07 | -0.61 | -157.0% | 7.18 | -4.3% | +0.4% | -4.3% | -8.4% | -9.2% | -15.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | Barclays | Maintains | Overweight → Overweight | — | $3.46 | $3.51 | +1.4% | +0.6% | +0.3% | -1.2% | -8.1% | -7.8% |
| Apr 10 | B. Riley Securities | Upgrade | Neutral → Buy | — | $3.44 | $3.70 | +7.6% | +4.7% | +0.9% | +1.5% | +2.3% | -0.9% |
| Mar 10 | Barclays | Maintains | Overweight → Overweight | — | $2.36 | $2.42 | +2.5% | +45.3% | +41.5% | +32.2% | +27.1% | +31.4% |
| Nov 3 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.66 | $1.65 | -0.6% | -4.8% | -12.7% | -13.3% | -18.1% | -17.5% |
| Aug 15 | Leerink Partners | Maintains | Outperform → Outperform | — | $1.62 | $1.60 | -1.2% | -2.5% | -6.2% | -8.0% | -8.0% | -11.1% |
| May 20 | B. Riley Securities | Maintains | Neutral → Neutral | — | $1.59 | $1.57 | -1.3% | -1.3% | -6.3% | -0.6% | -5.0% | -6.3% |
| May 14 | Stifel | Maintains | Hold → Hold | — | $1.54 | $1.52 | -1.3% | +0.6% | +0.0% | +2.6% | +3.2% | +1.9% |
| May 14 | Barclays | Maintains | Overweight → Overweight | — | $1.54 | $1.52 | -1.3% | +0.6% | +0.0% | +2.6% | +3.2% | +1.9% |
| Mar 25 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.96 | $1.89 | -3.6% | -8.7% | -20.4% | -24.5% | -35.7% | -35.2% |
| Nov 7 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $4.19 | $4.12 | -1.7% | +6.4% | +3.8% | +4.8% | -2.1% | -10.0% |
| Nov 6 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.77 | $4.59 | +21.8% | +11.1% | +18.3% | +15.4% | +16.4% | +8.8% |
| Sep 18 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.37 | $3.37 | +0.0% | -2.1% | +0.6% | -2.7% | -9.2% | -11.0% |
| Aug 21 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.62 | $3.61 | -0.3% | -0.6% | -8.0% | -3.6% | -1.7% | -5.2% |
| Aug 15 | Citigroup | Maintains | Buy → Buy | — | $3.34 | $3.43 | +2.7% | -2.4% | -3.3% | +6.3% | +8.4% | +7.8% |
| Aug 7 | BMO Capital | Maintains | Market Perform → Market Perform | — | $3.64 | $3.50 | -3.8% | -7.1% | -5.2% | -3.3% | -8.0% | -3.0% |
| Aug 1 | BTIG | Downgrade | Buy → Neutral | — | $3.76 | $3.71 | -1.3% | +6.4% | +1.9% | -4.8% | -3.2% | -10.1% |
| Aug 1 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.76 | $3.71 | -1.3% | +6.4% | +1.9% | -4.8% | -3.2% | -10.1% |
| Jul 31 | Barclays | Maintains | Overweight → Overweight | — | $5.25 | $3.68 | -29.9% | -28.4% | -23.8% | -27.0% | -31.8% | -30.7% |
| Jul 31 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.25 | $3.68 | -29.9% | -28.4% | -23.8% | -27.0% | -31.8% | -30.7% |
| Jul 31 | B. Riley Securities | Downgrade | Buy → Neutral | — | $5.25 | $3.68 | -29.9% | -28.4% | -23.8% | -27.0% | -31.8% | -30.7% |
| Jul 31 | Guggenheim | Downgrade | Buy → Neutral | — | $5.25 | $3.68 | -29.9% | -28.4% | -23.8% | -27.0% | -31.8% | -30.7% |
| Jul 29 | Barclays | Maintains | Overweight → Overweight | — | $5.55 | $5.55 | +0.0% | -1.4% | -5.4% | -32.3% | -27.9% | -31.0% |
| May 24 | BTIG | Maintains | Buy → Buy | — | $4.63 | $4.63 | +0.0% | -1.7% | -6.3% | -10.6% | -8.4% | -11.7% |
| May 13 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.31 | $3.51 | +6.0% | +32.3% | +34.4% | +42.3% | +54.7% | +32.0% |
| May 10 | TD Cowen | Downgrade | Buy → Hold | — | $14.67 | $4.53 | -69.1% | -77.4% | -70.1% | -69.7% | -67.9% | -65.1% |
| May 10 | Barclays | Maintains | Overweight → Overweight | — | $14.67 | $4.53 | -69.1% | -77.4% | -70.1% | -69.7% | -67.9% | -65.1% |
| May 10 | Stifel | Downgrade | Buy → Hold | — | $14.67 | $4.53 | -69.1% | -77.4% | -70.1% | -69.7% | -67.9% | -65.1% |
| May 10 | BMO Capital | Downgrade | Outperform → Market Perform | — | $14.67 | $4.53 | -69.1% | -77.4% | -70.1% | -69.7% | -67.9% | -65.1% |
| May 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $14.67 | $4.53 | -69.1% | -77.4% | -70.1% | -69.7% | -67.9% | -65.1% |
| Apr 9 | TD Cowen | Upgrade | Hold → Buy | — | $18.35 | $19.50 | +6.3% | -1.4% | -0.5% | +0.9% | -4.4% | -7.7% |
| Mar 11 | JMP Securities | Maintains | Outperform → Outperform | — | $17.43 | $17.15 | -1.6% | -2.8% | +1.0% | -5.0% | -7.9% | -8.6% |
| Mar 11 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $17.43 | $17.15 | -1.6% | -2.8% | +1.0% | -5.0% | -7.9% | -8.6% |
| Mar 11 | Citigroup | Maintains | Buy → Buy | — | $17.43 | $17.15 | -1.6% | -2.8% | +1.0% | -5.0% | -7.9% | -8.6% |
| Mar 8 | Barclays | Maintains | Overweight → Overweight | — | $20.51 | $19.34 | -5.7% | -15.0% | -17.4% | -14.2% | -19.3% | -21.7% |
| Mar 8 | Stifel | Maintains | Buy → Buy | — | $20.51 | $19.34 | -5.7% | -15.0% | -17.4% | -14.2% | -19.3% | -21.7% |
| Mar 8 | BMO Capital | Maintains | Outperform → Outperform | — | $20.51 | $19.34 | -5.7% | -15.0% | -17.4% | -14.2% | -19.3% | -21.7% |
| Mar 4 | BTIG | Maintains | Buy → Buy | — | $19.06 | $19.78 | +3.8% | +8.7% | +8.3% | +12.6% | +7.6% | -8.6% |
| Feb 29 | Barclays | Maintains | Overweight → Overweight | — | $17.19 | $17.84 | +3.8% | +4.4% | +10.9% | +20.5% | +20.1% | +24.9% |
| Feb 14 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $17.35 | $16.62 | -4.2% | -1.3% | +0.3% | -0.4% | -1.0% | -1.8% |
| Jan 24 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $12.01 | $12.55 | +4.5% | +0.0% | +6.6% | +10.1% | +13.6% | +16.6% |
| Dec 20 | Citigroup | Upgrade | Neutral → Buy | — | $9.23 | $10.08 | +9.2% | +6.5% | +8.3% | +6.9% | +9.5% | +7.9% |
| Nov 27 | Stifel | Maintains | Buy → Buy | — | $7.50 | $7.40 | -1.3% | +2.0% | -0.1% | +0.3% | +9.5% | +11.7% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.40 | $6.47 | +1.1% | -0.5% | +10.0% | +13.6% | +10.8% | +18.6% |
| Nov 7 | Guggenheim | Upgrade | Neutral → Buy | — | $5.44 | $5.87 | +7.9% | +17.1% | +26.7% | +20.4% | +17.6% | +17.1% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.98 | $5.12 | +2.8% | +24.3% | +19.1% | +11.6% | +7.6% | +5.0% |
| May 11 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.21 | $7.28 | +1.0% | -4.7% | -8.7% | -9.6% | -15.8% | -15.4% |
| Mar 21 | BTIG | Maintains | Buy → Buy | — | $6.69 | $6.87 | +2.7% | +6.4% | +0.3% | +3.9% | -0.1% | +0.9% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.65 | $6.80 | +2.3% | +0.6% | +7.1% | +0.9% | +4.5% | +0.5% |
| Mar 17 | Guggenheim | Downgrade | Buy → Neutral | — | $6.99 | $6.35 | -9.2% | -4.9% | -4.3% | +1.9% | -4.0% | -0.6% |
| Jan 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.39 | $5.25 | -2.6% | -2.6% | +7.4% | +8.9% | +15.6% | +15.4% |
No insider trades available.
8-K · 1.01
!! High
MacroGenics, Inc. -- 8-K 1.01: License Agreement
MacroGenics licensed technology to Sage Therapeutics for $60 million upfront, providing near-term revenue while validating its platform and potentially generating future royalties.
May 4
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
FDA's removal of the clinical hold on Magenta's lorigerlimab Phase 2 study de-risks development and allows trial resumption, potentially accelerating a promising dual-target immunotherapy toward commercialization.
Apr 8
8-K
MacroGenics, Inc. -- 8-K Filing
MacroGenics reported $189.9 million in cash with runway extending to late 2027, while advancing four programs including novel ADCs with Phase 1 readouts expected through late 2026.
Mar 9
8-K · 8.01
!! High
MacroGenics, Inc. -- 8-K 8.01: Material Event / Announcement
MacroGenics' CEO Siegel resigned for personal reasons, signaling potential leadership transition uncertainty for investors in this clinical-stage biopharmaceutical company.
Mar 2
8-K · 8.01
!! High
MacroGenics, Inc. -- 8-K 8.01: Material Event / Announcement
MacroGenics faces a setback as the FDA placed a partial clinical hold on its lorigerlimab Phase 2 gynecologic cancer study, potentially delaying development timelines and affecting the company's pipeline progress.
Feb 24
Data updated apr 26, 2026 12:07pm
· Source: massive.com